Prospectively randomized trial of postoperative adjuvant chemotherapy in patients with high-risk colon cancer

Michael J. O'Connell, John A. Laurie, Michael Kahn, Robert Joseph Fitzgibbons, Charles Erlichman, Lois Shepherd, Charles G. Moertel, Walter I. Kocha, Richard Pazdur, H. Sam Wieand, Joseph Rubin, Allen M. Vukov, John H. Donohue, James E. Krook, Alvaro Figueredo

Research output: Contribution to journalArticle

357 Citations (Scopus)

Abstract

Purpose: This study had two major goals: (1) to assess the effectiveness of a regimen of fluorouracil (5-FU) plus levamisole plus leucovorin as postoperative surgical adjuvant therapy for patients with high-risk colon cancer, and (2) to evaluate 6 months versus 12 months of chemotherapy. Patients and Methods: Patients with poor-prognosis stage II or III colon cancer were randomly assigned to receive adjuvant chemotherapy with either intensive-course 5-FU and leucovorin combined with levamisole, or a standard regimen of 5-FU plus levamisole. Patients were also randomly assigned to receive either 12 months or 6 months of chemotherapy, which resulted in four treatment groups. Results: Eight hundred ninety-one of 915 patients entered (97.4%) were eligible. The median follow-up duration is 5.1 years for patients still alive. There was a difference among the four treatment groups with re- spect to patient survival, and a significant duration-by-regimen interaction was observed. Specifically, standard 5-FU plus levamisole was inferior to 5-FU plus leucovorin plus levamisole when treatment was given for 6 months (5-year survival rate, 60% v 70%; P <.01). Conclusion: There was no significant improvement in patient survival when chemotherapy was given for 12 months compared with 6 months. When chemotherapy was given for 6 months, standard 5-FU plus levamisole was associated with inferior patient survival compared with intensive-course 5-FU plus leucovorin plus levamisole. These data suggest that 5-FU plus levamisole for 6 months should not be used in clinical practice, whereas 6 months of treatment with 5-FU plus leucovorin plus levamisole is effective.

Original languageEnglish
Pages (from-to)295-300
Number of pages6
JournalJournal of Clinical Oncology
Volume16
Issue number1
StatePublished - Jan 1998
Externally publishedYes

Fingerprint

Levamisole
Adjuvant Chemotherapy
Fluorouracil
Colonic Neoplasms
Leucovorin
Drug Therapy
Survival
Therapeutics
Survival Rate

All Science Journal Classification (ASJC) codes

  • Cancer Research
  • Oncology

Cite this

O'Connell, M. J., Laurie, J. A., Kahn, M., Fitzgibbons, R. J., Erlichman, C., Shepherd, L., ... Figueredo, A. (1998). Prospectively randomized trial of postoperative adjuvant chemotherapy in patients with high-risk colon cancer. Journal of Clinical Oncology, 16(1), 295-300.

Prospectively randomized trial of postoperative adjuvant chemotherapy in patients with high-risk colon cancer. / O'Connell, Michael J.; Laurie, John A.; Kahn, Michael; Fitzgibbons, Robert Joseph; Erlichman, Charles; Shepherd, Lois; Moertel, Charles G.; Kocha, Walter I.; Pazdur, Richard; Wieand, H. Sam; Rubin, Joseph; Vukov, Allen M.; Donohue, John H.; Krook, James E.; Figueredo, Alvaro.

In: Journal of Clinical Oncology, Vol. 16, No. 1, 01.1998, p. 295-300.

Research output: Contribution to journalArticle

O'Connell, MJ, Laurie, JA, Kahn, M, Fitzgibbons, RJ, Erlichman, C, Shepherd, L, Moertel, CG, Kocha, WI, Pazdur, R, Wieand, HS, Rubin, J, Vukov, AM, Donohue, JH, Krook, JE & Figueredo, A 1998, 'Prospectively randomized trial of postoperative adjuvant chemotherapy in patients with high-risk colon cancer', Journal of Clinical Oncology, vol. 16, no. 1, pp. 295-300.
O'Connell, Michael J. ; Laurie, John A. ; Kahn, Michael ; Fitzgibbons, Robert Joseph ; Erlichman, Charles ; Shepherd, Lois ; Moertel, Charles G. ; Kocha, Walter I. ; Pazdur, Richard ; Wieand, H. Sam ; Rubin, Joseph ; Vukov, Allen M. ; Donohue, John H. ; Krook, James E. ; Figueredo, Alvaro. / Prospectively randomized trial of postoperative adjuvant chemotherapy in patients with high-risk colon cancer. In: Journal of Clinical Oncology. 1998 ; Vol. 16, No. 1. pp. 295-300.
@article{52cbf2461b354422a4d1022a6bc3adda,
title = "Prospectively randomized trial of postoperative adjuvant chemotherapy in patients with high-risk colon cancer",
abstract = "Purpose: This study had two major goals: (1) to assess the effectiveness of a regimen of fluorouracil (5-FU) plus levamisole plus leucovorin as postoperative surgical adjuvant therapy for patients with high-risk colon cancer, and (2) to evaluate 6 months versus 12 months of chemotherapy. Patients and Methods: Patients with poor-prognosis stage II or III colon cancer were randomly assigned to receive adjuvant chemotherapy with either intensive-course 5-FU and leucovorin combined with levamisole, or a standard regimen of 5-FU plus levamisole. Patients were also randomly assigned to receive either 12 months or 6 months of chemotherapy, which resulted in four treatment groups. Results: Eight hundred ninety-one of 915 patients entered (97.4{\%}) were eligible. The median follow-up duration is 5.1 years for patients still alive. There was a difference among the four treatment groups with re- spect to patient survival, and a significant duration-by-regimen interaction was observed. Specifically, standard 5-FU plus levamisole was inferior to 5-FU plus leucovorin plus levamisole when treatment was given for 6 months (5-year survival rate, 60{\%} v 70{\%}; P <.01). Conclusion: There was no significant improvement in patient survival when chemotherapy was given for 12 months compared with 6 months. When chemotherapy was given for 6 months, standard 5-FU plus levamisole was associated with inferior patient survival compared with intensive-course 5-FU plus leucovorin plus levamisole. These data suggest that 5-FU plus levamisole for 6 months should not be used in clinical practice, whereas 6 months of treatment with 5-FU plus leucovorin plus levamisole is effective.",
author = "O'Connell, {Michael J.} and Laurie, {John A.} and Michael Kahn and Fitzgibbons, {Robert Joseph} and Charles Erlichman and Lois Shepherd and Moertel, {Charles G.} and Kocha, {Walter I.} and Richard Pazdur and Wieand, {H. Sam} and Joseph Rubin and Vukov, {Allen M.} and Donohue, {John H.} and Krook, {James E.} and Alvaro Figueredo",
year = "1998",
month = "1",
language = "English",
volume = "16",
pages = "295--300",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "1",

}

TY - JOUR

T1 - Prospectively randomized trial of postoperative adjuvant chemotherapy in patients with high-risk colon cancer

AU - O'Connell, Michael J.

AU - Laurie, John A.

AU - Kahn, Michael

AU - Fitzgibbons, Robert Joseph

AU - Erlichman, Charles

AU - Shepherd, Lois

AU - Moertel, Charles G.

AU - Kocha, Walter I.

AU - Pazdur, Richard

AU - Wieand, H. Sam

AU - Rubin, Joseph

AU - Vukov, Allen M.

AU - Donohue, John H.

AU - Krook, James E.

AU - Figueredo, Alvaro

PY - 1998/1

Y1 - 1998/1

N2 - Purpose: This study had two major goals: (1) to assess the effectiveness of a regimen of fluorouracil (5-FU) plus levamisole plus leucovorin as postoperative surgical adjuvant therapy for patients with high-risk colon cancer, and (2) to evaluate 6 months versus 12 months of chemotherapy. Patients and Methods: Patients with poor-prognosis stage II or III colon cancer were randomly assigned to receive adjuvant chemotherapy with either intensive-course 5-FU and leucovorin combined with levamisole, or a standard regimen of 5-FU plus levamisole. Patients were also randomly assigned to receive either 12 months or 6 months of chemotherapy, which resulted in four treatment groups. Results: Eight hundred ninety-one of 915 patients entered (97.4%) were eligible. The median follow-up duration is 5.1 years for patients still alive. There was a difference among the four treatment groups with re- spect to patient survival, and a significant duration-by-regimen interaction was observed. Specifically, standard 5-FU plus levamisole was inferior to 5-FU plus leucovorin plus levamisole when treatment was given for 6 months (5-year survival rate, 60% v 70%; P <.01). Conclusion: There was no significant improvement in patient survival when chemotherapy was given for 12 months compared with 6 months. When chemotherapy was given for 6 months, standard 5-FU plus levamisole was associated with inferior patient survival compared with intensive-course 5-FU plus leucovorin plus levamisole. These data suggest that 5-FU plus levamisole for 6 months should not be used in clinical practice, whereas 6 months of treatment with 5-FU plus leucovorin plus levamisole is effective.

AB - Purpose: This study had two major goals: (1) to assess the effectiveness of a regimen of fluorouracil (5-FU) plus levamisole plus leucovorin as postoperative surgical adjuvant therapy for patients with high-risk colon cancer, and (2) to evaluate 6 months versus 12 months of chemotherapy. Patients and Methods: Patients with poor-prognosis stage II or III colon cancer were randomly assigned to receive adjuvant chemotherapy with either intensive-course 5-FU and leucovorin combined with levamisole, or a standard regimen of 5-FU plus levamisole. Patients were also randomly assigned to receive either 12 months or 6 months of chemotherapy, which resulted in four treatment groups. Results: Eight hundred ninety-one of 915 patients entered (97.4%) were eligible. The median follow-up duration is 5.1 years for patients still alive. There was a difference among the four treatment groups with re- spect to patient survival, and a significant duration-by-regimen interaction was observed. Specifically, standard 5-FU plus levamisole was inferior to 5-FU plus leucovorin plus levamisole when treatment was given for 6 months (5-year survival rate, 60% v 70%; P <.01). Conclusion: There was no significant improvement in patient survival when chemotherapy was given for 12 months compared with 6 months. When chemotherapy was given for 6 months, standard 5-FU plus levamisole was associated with inferior patient survival compared with intensive-course 5-FU plus leucovorin plus levamisole. These data suggest that 5-FU plus levamisole for 6 months should not be used in clinical practice, whereas 6 months of treatment with 5-FU plus leucovorin plus levamisole is effective.

UR - http://www.scopus.com/inward/record.url?scp=0031982505&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031982505&partnerID=8YFLogxK

M3 - Article

VL - 16

SP - 295

EP - 300

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 1

ER -